InnoCan Pharma Leads Our Trio Of TSX Penny Stock Picks

In This Article:

The Canadian market has experienced some pullback recently, driven by political uncertainty and profit-taking after a strong year of growth. Despite this volatility, the underlying economic fundamentals remain robust, providing a landscape where smaller companies can thrive. Penny stocks, though often overlooked due to their historical connotations, continue to offer intriguing opportunities for investors seeking value and growth potential in financially sound enterprises.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Mandalay Resources (TSX:MND)

CA$4.19

CA$393.48M

★★★★★★

Findev (TSXV:FDI)

CA$0.445

CA$12.75M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.29

CA$116.42M

★★★★★★

Silvercorp Metals (TSX:SVM)

CA$4.36

CA$948.57M

★★★★★★

PetroTal (TSX:TAL)

CA$0.54

CA$492.49M

★★★★★★

Foraco International (TSX:FAR)

CA$2.31

CA$227.38M

★★★★★☆

NamSys (TSXV:CTZ)

CA$1.25

CA$33.58M

★★★★★★

East West Petroleum (TSXV:EW)

CA$0.04

CA$3.62M

★★★★★★

Tornado Infrastructure Equipment (TSXV:TGH)

CA$1.13

CA$101.79M

★★★★★☆

Hemisphere Energy (TSXV:HME)

CA$1.83

CA$178.48M

★★★★★☆

Click here to see the full list of 958 stocks from our TSX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

InnoCan Pharma

Simply Wall St Financial Health Rating: ★★★★★★

Overview: InnoCan Pharma Corporation is a pharmaceutical technology company that develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients across the United States, Canada, Europe, and internationally, with a market cap of CA$60.26 million.

Operations: The company generates revenue primarily from online sales, amounting to $28.86 million, with additional income from other operations totaling $0.07 million.

Market Cap: CA$60.26M

InnoCan Pharma, with a market cap of CA$60.26 million, has shown promising developments despite being unprofitable. Recent earnings indicate a significant reduction in net losses and an increase in sales to US$24.04 million for the first nine months of 2024. The company remains debt-free, which is advantageous for financial stability, although shareholders have experienced dilution over the past year. Positive results from safety assessments and compassionate therapy studies highlight potential future applications for its liposomal-CBD products. A recent private placement aims to raise CAD 700,000, potentially supporting further research and development efforts.